GCG and Parkinson disease: Glucagon-like peptide-1 (GLP-1) was reported as a potential candidate in modifying neurodegenerative diseases as a promising antiparkinsonian effect of dipeptidyl peptidase (DPP)-4 inhibitors (Gliptins) by exerting a neuroprotective effect in PD animal models2,3.